Description
Tesa + Ipa Blend is a research formulation with two GH-stimulating peptides in one injection: Tesamorelin (Tesa) as GHRH analog and Ipamorelin (Ipa) as selective ghrelin receptor agonist (GHRP).
Per study reports the formulation combines two complementary GH stimulation pathways:
- Tesamorelin as stabilized form of human GHRH (Growth Hormone Releasing Hormone) - activates the GHRH receptor in the pituitary and stimulates natural GH secretion. Clinically approved for HIV-associated lipodystrophy treatment (Egrifta).
- Ipamorelin as selective ghrelin receptor agonist without significant stimulation of cortisol or prolactin (unlike GHRP-6, GHRP-2). Acts synergistically with GHRH activation.
The combination of two independent pathways yields substantially higher GH pulses than each compound alone. Response is physiological (pulsatile) unlike exogenous rhGH, preserving the natural feedback loop.
Typical application is subcutaneous before sleep or pre-workout, in 8-12 week courses.
You can order Tesa + Ipa Blend as lyophilized peptide in 10-pack at 17mg per vial (11+6 split).
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Tesa + Ipa Blend is considered well tolerated per study reports. Both components - Tesamorelin and Ipamorelin - stimulate the body’s own GH secretion in a pulsatile, physiological pattern, preserving the natural feedback loop.
Observed in research and user reports:
- Injection site: mild redness, pressure or transient irritation at the injection site is the most common observation with subcutaneous use.
- GH-typical effects: as is common with GH secretagogues, the literature describes transient water retention as well as numbness or tingling in the hands (carpal-tunnel-type symptoms), usually dose-dependent and reversible.
- Glucose metabolism: elevated GH levels can raise fasting blood glucose and transiently reduce insulin sensitivity in studies.
- Fatigue: brief fatigue or grogginess after application is occasionally reported, consistent with the GH peak.
- No long-term data: a substantial clinical database exists for Tesamorelin, but robust long-term data on research use of the blend combination is lacking. The profile rests primarily on short-term studies and anecdotal experience.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV - NEJM 2007, Falutz et al: pivotal Tesamorelin study on HIV-associated lipodystrophy.
- Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat - JCEM 2010, Falutz et al: pooled analysis of the two Phase 3 trials with safety extension.
- Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation - AIDS 2008, Falutz et al: long-term safety data.
- Ipamorelin, the first selective growth hormone secretagogue - European Journal of Endocrinology 1998, Raun et al: classic selectivity study showing Ipamorelin action without cortisol or prolactin rise.
- The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats - Journal of Endocrinology 2000, Svensson et al: preclinical study on long-term Ipamorelin effects.
